Literature DB >> 17982646

Relation between telomerase activity, hTERT and telomere length for intracranial tumours.

L Maes1, L Van Neste, K Van Damme, J P O Kalala, L De Ridder, S Bekaert, M Cornelissen.   

Abstract

Human linear chromosomes are capped by specialized DNA-protein structures called telomeres. The present study analysed the telomerase activity, hTERT protein and telomere length in meningiomas and gliomas in relation to their WHO grading. Fifty-three freshly dissected tumour biopsies were analysed for telomerase activity, hTERT protein expression and telomere length. Telomerase activity was examined in 41 of the 53 biopsies. Telomerase activity was detected in 3 of 35 (8.6%) screened meningiomas (1 benign, 1 atypical and 1 malignant meningioma). For hTERT expression, 56.4% of meningiomas were positive with a mean labelling index (hTERT LI) of 31.3% (SD=26.5) for the hTERT positive meningiomas. The mean telomere length for meningiomas was 6.983 kb (SD=1.969). For gliomas, no active telomerase was detected in 2 low-grade astrocytomas, whereas three of the four screened glioblastomas were positive for telomerase activity. The only hTERT protein positive astrocytoma had a mean labelling index of 9.0%. On the other hand, the hTERT LI for glioblastomas was 53.6% (SD=28.0). The two low-grade astrocytomas had a telomere length of 14.310 and 9.236 kb. The anaplastic astrocytoma had a telomere length of 4.903 kb and the glioblastomas 5.767 kb (SD=2.042). The normal meningeal and neuronal tissue is negative for telomerase activity and hTERT. The length was +/-10.000 kb. These results indicate that telomere shortening may be a critical step in pathogenesis of atypical and malignant meningiomas and gliomas. Critical telomere shortening in vitro was shown to activate telomerase.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17982646     DOI: 10.3892/or.18.6.1571

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  13 in total

1.  Alterations of telomere length in human brain tumors.

Authors:  Majid Kheirollahi; Masoud Mehrazin; Naser Kamalian; Parvin Mehdipour
Journal:  Med Oncol       Date:  2010-04-07       Impact factor: 3.064

Review 2.  Pharmacotherapeutic management of pediatric gliomas : current and upcoming strategies.

Authors:  Trent R Hummel; Lionel M Chow; Maryam Fouladi; David Franz
Journal:  Paediatr Drugs       Date:  2013-02       Impact factor: 3.022

3.  hTERT promoter methylation in meningiomas and central nervous hemangiopericytomas.

Authors:  Gina Fürtjes; Michaela Köchling; Susanne Peetz-Dienhart; Andrea Wagner; Katharina Heß; Martin Hasselblatt; Volker Senner; Walter Stummer; Werner Paulus; Benjamin Brokinkel
Journal:  J Neurooncol       Date:  2016-07-27       Impact factor: 4.130

4.  Telomere length and risk of glioma.

Authors:  Farzana Walcott; Preetha Rajaraman; Shahinaz M Gadalla; Peter D Inskip; Mark P Purdue; Demetrius Albanes; Esther Orr; Immaculata De Vivo; Sharon A Savage
Journal:  Cancer Epidemiol       Date:  2013-11-11       Impact factor: 2.984

5.  Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age.

Authors:  Daniela Lötsch; Bahil Ghanim; Magdalena Laaber; Gabriele Wurm; Serge Weis; Stefan Lenz; Gerald Webersinke; Josef Pichler; Walter Berger; Sabine Spiegl-Kreinecker
Journal:  Neuro Oncol       Date:  2013-02-07       Impact factor: 12.300

6.  Prognostic significance of telomere maintenance mechanisms in pediatric high-grade gliomas.

Authors:  Kathleen Dorris; Matthew Sobo; Arzu Onar-Thomas; Eshini Panditharatna; Charles B Stevenson; Sharon L Gardner; Mariko D Dewire; Christopher R Pierson; Randal Olshefski; Sandra A Rempel; Stewart Goldman; Lili Miles; Maryam Fouladi; Rachid Drissi
Journal:  J Neurooncol       Date:  2014-01-30       Impact factor: 4.130

7.  Development of patient-derived xenograft models from a spontaneously immortal low-grade meningioma cell line, KCI-MENG1.

Authors:  Sharon K Michelhaugh; Anthony R Guastella; Kaushik Varadarajan; Neil V Klinger; Prahlad Parajuli; Aamir Ahmad; Seema Sethi; Amro Aboukameel; Sam Kiousis; Ian M Zitron; Salah A Ebrahim; Lisa A Polin; Fazlul H Sarkar; Aliccia Bollig-Fischer; Sandeep Mittal
Journal:  J Transl Med       Date:  2015-07-15       Impact factor: 5.531

8.  Potential clinical role of telomere length in human glioblastoma.

Authors:  D La Torre; M Aguennouz; A Conti; M Giusa; G Raffa; R V Abbritti; A Germano'; F F Angileri
Journal:  Transl Med UniSa       Date:  2011-10-17

9.  CTC1 increases the radioresistance of human melanoma cells by inhibiting telomere shortening and apoptosis.

Authors:  Y M Luo; N X Xia; L Yang; Z Li; H Yang; H J Yu; Y Liu; H Lei; F X Zhou; C H Xie; Y F Zhou
Journal:  Int J Mol Med       Date:  2014-04-02       Impact factor: 4.101

10.  Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility.

Authors:  Margaret Wrensch; Robert B Jenkins; Jeffrey S Chang; Ru-Fang Yeh; Yuanyuan Xiao; Paul A Decker; Karla V Ballman; Mitchel Berger; Jan C Buckner; Susan Chang; Caterina Giannini; Chandralekha Halder; Thomas M Kollmeyer; Matthew L Kosel; Daniel H LaChance; Lucie McCoy; Brian P O'Neill; Joe Patoka; Alexander R Pico; Michael Prados; Charles Quesenberry; Terri Rice; Amanda L Rynearson; Ivan Smirnov; Tarik Tihan; Joe Wiemels; Ping Yang; John K Wiencke
Journal:  Nat Genet       Date:  2009-07-05       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.